title: Serum hepatocyte growth factor levels and the effects of antidepressants in panic disorder.
abstract: Previous animal studies have suggested that hepatocyte growth factor (HGF) could be associated with depression- and anxiety-related behaviors. Our aim was to relate serum HGF levels with State-Trait Anxiety Inventory (STAI), Profile of Mood State (POMS), and Revised NEO Personality Inventory (NEO-PI-R) scores in patients with panic disorder (with or without agoraphobia) and healthy controls. We examined 67 patients with panic disorders and 97 controls. Patients were split into two groups according to whether they exhibited a 50% improvement in test scores (good/high response group: n = 26) or not (poor/low response group: n = 41). In both healthy control and panic disorder individuals, there were no significant associations between HGF serum levels and STAI or NEO-PI-R scores. However, there was a significant correlation between serum HGF levels and fatigue in healthy control subjects in as scored by POMS testing. HGF concentration in the good/high response group was significantly elevated compared to both the low/poor response group (p < 0.01) and the control group (p < 0.01). HGF levels in the poor response group did not differ from the control group (p = 0.48). These results indicate that increased serum HGF levels might be a requirement for antidepressant efficacy in patients with panic disorders.
authors.affiliation: Department of Neuropsychiatry, Oita University Faculty of Medicine, Oita 879-5593, Japan.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Kanehisa
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Ishitobi
authors.forename: Tomoko
authors.initials: T
authors.lastname: Ando
authors.forename: Shizuko
authors.initials: S
authors.lastname: Okamoto
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Maruyama
authors.forename: Kentaro
authors.initials: K
authors.lastname: Kohno
authors.forename: Taiga
authors.initials: T
authors.lastname: Ninomiya
authors.forename: Haruka
authors.initials: H
authors.lastname: Higuma
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Jusen
authors.initials: J
authors.lastname: Tsuru
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Hanada
authors.forename: Kensuke
authors.initials: K
authors.lastname: Kodama
authors.forename: Jotaro
authors.initials: J
authors.lastname: Akiyoshi
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000704:Analysis of Variance; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D016009:Chi-Square Distribution; D004797:Enzyme-Linked Immunosorbent Assay; D005221:Fatigue / Q000097:blood; D005260:Female; D017228:Hepatocyte Growth Factor / Q000097:blood*; D006801:Humans; D008297:Male; D016584:Panic Disorder / Q000097:blood* / Q000188:drug therapy*; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D017228:Hepatocyte Growth Factor; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase